Dr Simó Schwartz Jr, director of the CIBBIM-Nanomedicine at Vall d’Hebron Institute of Research (VHIR), has been appointed member of the editorial board of the European Journal of Nanomedicine. VHIR’s researcher will review some of the manuscripts submitted to the prestigious scientific journal for the next two years.
The journal focuses on the spectrum from nano(bio)technological engineering and characterization to clinically translatable innovative prevention, diagnostics, and therapies. Thus, the readership is multidisciplinary, including scientists in chemistry, physics, engineering, pharmacology, molecular biology, biomedicine, and clinicians, addressing recipients in academic, industrial, and regulatory environments, the informed public and policymakers.
Last summer, the editors of the journal and European experts in this field participated at the European Summit for Clinical Nanomedicine and Targeted Medicine, which took place in Basel (Switzerland). Dr Schwartz played an important role in this conference, presenting the latest advances of his team in cancer stem cells and personalized cancer nanomedicine.
